JAK-IN-20

• UNSPSC Description:

  JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC50s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo[1].

• Target Antigen:

  JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/jak-in-20.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(NCC#N)C1=CC=C(C2=NC(NC3=CC=C(N4CCC(N5CCOCC5)CC4)C=C3)=NC=C2F)C=C1

• Molecular Weight:

  515.58

• References & Citations:

  [1]Desai J, et al. Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor. Bioorg Med Chem Lett. 2022; 66:128728.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1654776-91-6